2-{4-[4-(6,8-dimethyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazin-7-yl)-pyrimidin-2-ylamino]-phenyl}-N-(2-methoxy-ethyl)-acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-{4-[4-(6,8-dimethyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazin-7-yl)-pyrimidin-2-ylamino]-phenyl}-N-(2-methoxy-ethyl)-acetamide
• 英文别名: 2-[4-[[4-(6,8-dimethyl-1-oxo-3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-7-yl)pyrimidin-2-yl]amino]phenyl]-N-(2-methoxyethyl)acetamide
• 化学式: C₂₄H₂₈N₆O₃
• 分子量: 448.525
• InChiKey: USDQQQNFAALYPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  {4-[4-(6,8-dimethyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazin-7-yl)-pyrimidin-2-ylamino]-phenyl}-acetic acid 、 2-甲氧基乙胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 、 甲酸 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 以47%的产率得到2-{4-[4-(6,8-dimethyl-1-oxo-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazin-7-yl)-pyrimidin-2-ylamino]-phenyl}-N-(2-methoxy-ethyl)-acetamide
  参考文献：
  名称：

  WO2007/42784

  摘要：

  公开号：

文献信息

• Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds
  申请人：Jones Stuart

  公开号：US20100035870A1

  公开（公告）日：2010-02-11

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein Z is NR 11 , NHCO, NHSO 2 , NHCH 2 , CH 2 , CH 2 CH 2 , or CH═CH; X is a hydrocarbyl group optionally substituted by one or more R 12 groups; R 10 and R 11 are each independently II or alkyl; R 1 -R 4 are each independently II or (CII 2 ) m R 12 , where m is O, 1, 2, or 3; each R 12 is independently (CH 2 ) a R 16 , where each R 16 is independently selected from O(CH 2 ) b R 13 , R 13 , COR 13 , COOR 13 , CN, CONR 13 R 14 , NR 13 R 14 , NR 13 COR 14 , SR 13 , SOR 13 , SO 2 R 13 , NR 13 SO 2 R 14 , SO 2 OR 13 , SO 2 NR 13 R 14 , halogen, CF 3 , and NO 2 , and wherein each a is 0, 1, 2, or 3 and b is 0, 1, 2, or 3; R 13 and R 14 are each independently H or (CH 2 ) n R 15 , where n is 0, 1, 2, or 3; and each R 15 is independently selected from alkyl, cycloalkyl, heteroaryl, aralkyl, aryl and heterocycloalkyl, each of which may be optionally substituted by one or more substituents selected from halogen, OH, CN, COO-alkyl, aralkyl, SO 2 -alkyl, SO 2 -aryl, COOH, CO— alkyl, CO-aryl, NH 2 , NH-alkyl, N(alkyl) 2 , CF 3 , alkyl and alkoxy, wherein said alkyl and alkoxy groups may be further substituted by one or more OH groups. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula I, and the use of compounds of formula (I) in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中Z是NR11，NHCO，NHSO2，NHCH2，CH2，CH2CH2或CH═CH；X是一个烃基团，可以选择地被一个或多个R12基团取代；R10和R11分别独立地为II或烷基；R1-R4分别独立地为II或(CII2)mR12，其中m为O，1，2或3；每个R12独立地为(CH2)aR16，其中每个R16独立地选自O(CH2)bR13，R13，COR13，COOR13，CN，CONR13R14，NR13R14，NR13COR14，SR13，SOR13，SO2R13，NR13SO2R14，SO2OR13，SO2NR13R14，卤素，CF3和NO2，其中每个a为0，1，2或3，b为0，1，2或3；R13和R14独立地为H或(CH2)nR15，其中n为0，1，2或3；每个R15独立地选自烷基，环烷基，杂环芳基，芳基烷基，芳基和杂环烷基，每个可以选择地被一个或多个取代基取代，所述取代基选自卤素，OH，CN，COO-烷基，芳基烷基，SO2-烷基，SO2-芳基，COOH，CO-烷基，CO-芳基，NH2，NH-烷基，N（烷基）2，CF3，烷基和烷氧基，其中所述烷基和烷氧基可以进一步被一个或多个OH基取代。本发明的其他方面涉及包含式(I)的化合物的药物组合物，以及使用式(I)的化合物制备用于治疗各种疾病，包括增殖性疾病、病毒性疾病、中风等的药物。
• Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds
  申请人：Jones Stuart

  公开号：US08404692B2

  公开（公告）日：2013-03-26

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein Z is NR11, NHCO, NHSO2, NHCH2, CH2, CH2CH2, or CH═CH; X is a hydrocarbyl group optionally substituted by one or more R12 groups; R10 and R11 are each independently II or alkyl; R1-R4 are each independently II or (CII2)mR12, where m is O, 1, 2, or 3; each R12 is independently (CH2)aR16, where each R16 is independently selected from O(CH2)bR13, R13, COR13, COOR13, CN, CONR13R14, NR13R14, NR13COR14, SR13, SOR13, SO2R13, NR13SO2R14, SO2OR13, SO2NR13R14, halogen, CF3, and NO2, and wherein each a is 0, 1, 2, or 3 and b is 0, 1, 2, or 3; R13 and R14 are each independently H or (CH2)aR15, where n is 0, 1, 2, or 3; and each R15 is independently selected from alkyl, cycloalkyl, heteroaryl, aralkyl, aryl and heterocycloalkyl, each of which may be optionally substituted by one or more substituents selected from halogen, OH, CN, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy, wherein said alkyl and alkoxy groups may be further substituted by one or more OH groups. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula I, and the use of compounds of formula (I) in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中Z是NR11，NHCO，NHSO2，NHCH2，CH2，CH2CH2或CH═CH；X是一个可选地被一个或多个R12基团取代的烃基；R10和R11各自独立地是II或烷基；R1-R4各自独立地是II或（CII2）mR12，其中m是0、1、2或3；每个R12独立地是（CH2）aR16，其中每个R16独立地从O(CH2)bR13，R13，COR13，COOR13，CN，CONR13R14，NR13R14，NR13COR14，SR13，SOR13，SO2R13，NR13SO2R14，SO2OR13，SO2NR13R14，卤素，CF3和NO2中选择，其中每个a是0、1、2或3，b是0、1、2或3；R13和R14各自独立地是H或（CH2）aR15，其中n是0、1、2或3；每个R15独立地从烷基，环烷基，杂环芳基，芳基和杂环烷基中选择，每个基团可以选择性地被一个或多个卤素，OH，COO-烷基，芳基烷基，SO2-烷基，SO2-芳基，COOH，CO-烷基，CO-芳基，NH2，NH-烷基，N（烷基）2，CF3，烷基和烷氧基中的一个或多个取代，其中所述的烷基和烷氧基基团可以进一步被一个或多个OH基团取代。本发明的进一步方面涉及包含式(I)的化合物的制药组合物以及将式(I)的化合物用于制备用于治疗多种疾病，包括增殖性疾病，病毒性疾病，中风等的药物。
• PYRIMIDIN-4-YL-3,4-DIHYDRO-2H-PYRROLO[1,2A]PYRAZIN-1-ONE COMPOUNDS
  申请人：Cyclacel Limited

  公开号：EP1940846B9

  公开（公告）日：2012-09-12
• US8404692B2
  申请人：——

  公开号：US8404692B2

  公开（公告）日：2013-03-26
• [EN] COMPOUND<br/>[FR] COMPOSE
  申请人：CYCLACEL LTD

  公开号：WO2007042784A2

  公开（公告）日：2007-04-19

  [EN] The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein Z is NR¹¹, NHCO, NHSO₂, NHCH₂, CH₂, CH₂CH₂, or CH=CH; X is a hydrocarbyl group optionally substituted by one or more R¹² groups; R¹⁰ and R¹¹ are each independently H or alkyl; R¹ -R⁴ are each independently H or (CH₂)_mR¹², where m is O, 1, 2, or 3; each R¹² is independently (CH₂)_aR¹⁶, where each R¹⁶ is independently selected from O(CH₂)_bR¹³, R¹³, COR¹³, COOR¹³, CN, CONR¹³R¹⁴, NR¹³R¹⁴, NR¹³COR¹⁴, SR¹³, SOR¹³, SO₂R¹³, NR¹³SO₂R¹⁴, SO₂OR¹³, SO₂NR¹³R¹⁴, halogen, CF₃, and NO₂, and wherein each a is 0, 1, 2, or 3 and b is 0, 1, 2, or 3; R¹³ and R¹⁴ are each independently H or (CH₂)_nR¹⁵, where n is 0, 1, 2, or 3; and each R¹⁵ is independently selected from alkyl, cycloalkyl, heteroaryl, aralkyl, aryl and heterocycloalkyl, each of which may be optionally substituted by one or more substituents selected from halogen, OH, CN, COO-alkyl, aralkyl, SO₂-alkyl, SO₂-aryl, COOH, CO- alkyl, CO-aryl, NH₂, NH-alkyl, N(alkyl)₂, CF₃, alkyl and alkoxy, wherein said alkyl and alkoxy groups may be further substituted by one or more OH groups. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula I, and the use of compounds of formula (I) in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.
  [FR] La présente invention concerne des composés de formule (I), ou des sels pharmaceutiquement acceptables de ces composés. Dans cette formule, Z est NR¹¹, NHCO, NHSO₂, NHCH₂, CH₂, CH₂CH₂ ou CH=CH, X est un groupe hydrocarbyle éventuellement substitué par un ou plusieurs groupes, R¹², R¹⁰ et R¹¹ sont chacun indépendamment H ou alkyle, R¹-R⁴ sont chacun indépendamment H ou (CH₂)_mR¹², où m est 0, 1, 2 ou 3, chaque R¹² est indépendamment (CH₂)_aR¹⁶, où chaque R¹⁶ est indépendamment choisi parmi O(CH₂)_bR¹³, R¹³, COR¹³, COOR¹³, CN, CONR¹³R¹⁴, NR¹³R¹⁴, NR¹³COR¹⁴, SR¹³, SOR¹³, SO₂R¹³, NR¹³SO₂R¹⁴, SO₂OR¹³, SO₂NR¹³R¹⁴, halogène, CF₃ et NO₂, chaque a étant 0, 1, 2 ou 3 et chaque b étant 0, 1, 2 ou 3, R¹³ et R¹⁴ sont chacun indépendamment H ou (CH₂)_nR¹⁵, où n est 0, 1, 2 ou 3, et chaque R¹⁵ est indépendamment choisi parmi alkyle, cycloalkyle, hétéroaryle, aralkyle, aryle et hétérocycloalkyle, chacun de ces constituants pouvant éventuellement être substitué par un ou plusieurs substituants choisis parmi halogène, OH, CN, COO-alkyle, aralkyle, SO₂-alkyle, SO₂-aryle, COOH, CO-alkyle, CO-aryle, NH₂, NH-alkyle, N(alkyl)₂, CF₃, alkyle et alcoxy, les groupes alkyle et alcoxy pouvant encore être substitués par un ou plusieurs groupes OH. D'autres aspects de l'invention concernent des compositions pharmaceutiques comprenant les composés de formule (I), ainsi que l'utilisation de ces composés de formule (I) dans la préparation d'un médicament destiné à traiter une pluralité de troubles, tels que les troubles prolifératifs, les troubles viraux, l'accident cérébrovasculaire, etc.